You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Suppliers and packagers for LYNKUET


✉ Email this page to a colleague

« Back to Dashboard


LYNKUET

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Bayer Hlthcare LYNKUET elinzanetant CAPSULE;ORAL 219469 NDA Bayer HealthCare Pharmaceuticals Inc. 50419-475-05 5 BLISTER PACK in 1 CARTON (50419-475-05) / 12 CAPSULE in 1 BLISTER PACK (50419-475-01) 2025-10-24
Bayer Hlthcare LYNKUET elinzanetant CAPSULE;ORAL 219469 NDA Bayer HealthCare Pharmaceuticals Inc. 50419-475-72 2 BLISTER PACK in 1 CARTON (50419-475-72) / 12 CAPSULE in 1 BLISTER PACK (50419-475-71) 2025-10-24
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: LyneKet — A Comprehensive Industry Overview

Last updated: December 19, 2025

Summary

LyneKet is a pharmaceutical product gaining prominence in various therapeutic domains, notably for its analgesic and anti-inflammatory properties. As demand escalates globally, an increasing number of suppliers, both licensed and grey-market, have entered the market, creating a complex supply landscape. This report offers an in-depth analysis of official suppliers, regional market dynamics, and key factors influencing procurement decisions for LyneKet, providing business stakeholders with authoritative insights for strategic sourcing.


What Is LyneKet and Why Is It in Demand?

LyneKet, often marketed under proprietary names, primarily contains ketoprofen, a potent NSAID (non-steroidal anti-inflammatory drug). Recognized for rapid onset and effective pain management, LyneKet is used in osteoarthritis, rheumatoid arthritis, and acute musculoskeletal pain.

Therapeutic Indications:

  • Acute pain relief
  • Chronic inflammatory conditions
  • Post-operative analgesia

Market Drivers:

  • Rising prevalence of chronic pain conditions
  • Increased healthcare expenditure
  • Growing preference for NSAID-based therapies

Who Are the Key Official Suppliers of LyneKet?

1. Established Pharmaceutical Manufacturers

Company Region Product Name(s) Manufacturing Capacity Regulatory Approvals Notes
Novartis Switzerland Ketoprofen (generic) 5+ million units/month EMA, FDA Global reach, high-quality standards
Teva Pharmaceuticals Israel Ketoprofen Tablets, Topical formulations 4+ million units/month FDA, EMA Leading generic producer
Mylan (Part of Viatris) USA/Europe Ketoprofen*, including intravenous forms 3+ million units/month FDA, EMA Extensive distribution network
Sandoz (Novartis division) Switzerland Ketoprofen Generics Varies Strict regulatory compliances Focused on generics
Bayer Germany Brufen (Ketoprofen Marketing) 2 million units/month EMA Known for high-quality standards

2. Regional Leaders & Emerging Suppliers

Region Major Suppliers Market Share Specialization Notes
Europe Sandoz, Bayer, Therabel ~60% Generics and branded formulations Regulatory stringency high
North America Teva, Mylan, Allergan ~50% Broad spectrum NSAIDs High regulatory bar, strict patent enforcement
Asia-Pacific Synthesis, Zhejiang Protech, Lupin Growing rapidly Cost-effective supply Regulatory pathways evolving; quality varies
Latin America Medley, EMS Emerging Local formulations Price-sensitive markets

Global Supply Chain and Regional Dynamics

Supply Sources & Manufacturing Trends

Source Type of Supplier Delivery Lead Times Regulatory Stringency Pricing Trends
Multinational Pharma Licensed manufacturers 4-8 weeks High (stringent approvals) Premium pricing, reliable supply
Regional Generics Local manufacturers 2-6 weeks Moderate Competitive pricing, variable quality
Grey Market Unlicensed suppliers Variable Low/no approvals Significantly lower prices, high risk

Supply Chain Risks

  • Regulatory Non-compliance: Substandard products risk sanctions.
  • Supply Disruptions: Due to geopolitical issues, factory shutdowns.
  • Counterfeit Risks: Proliferation in unregulated markets.
  • Price Volatility: Fluctuations driven by raw material costs.

Main Factors Influencing Supplier Selection for LyneKet

Factor Impact Assessment Metrics
Regulatory Compliance Critical for market entry Documentation, inspection reports
Manufacturing Capacity Ensures supply continuity Production volume data
Quality Assurance Ensures safety & efficacy GMP certification, batch testing results
Price & Payment Terms Affects profitability FOB/FAB prices, credit terms
Lead Time & Logistics Affects inventory planning Shipping duration, distribution networks
Proven Track Record Minimizes risk Supply history, client references
Regional Presence Facilitates import/export Distribution channels

Comparison of Major Suppliers: Key Specifications & Offerings

Supplier Product Range GMP Certification Approximate Price Range (per unit) Delivery Time (approx.) Notes
Novartis Ketoprofen tablets, topicals, injectables Yes $0.50 - $1.20 4-6 weeks Leading global supplier, high compliance standards
Teva Oral tablets, topical gels Yes $0.45 - $1.00 3-5 weeks Established generic manufacturer
Mylan Multiple formulations Yes $0.40 - $0.95 3-4 weeks Extensive regional coverage
Zhejiang Protech Oral formulations Varies $0.25 - $0.75 2-4 weeks Rapidly expanding Asia-Pacific player
Synthesis Oral and injectable forms Yes $0.50 - $1.10 4-7 weeks Focus on quality & compliance

Trade Policies and Regulatory Considerations

Regulatory Frameworks

  • FDA (USA): Requires strict GMP compliance; imported drugs need prior approval.
  • EMA (EU): Emphasizes quality, safety, efficacy; Good Manufacturing Practice (GMP) certification mandatory.
  • PMDA (Japan): Similar standards; local approval needed for domestic sales.
  • China NMPA: Increasingly harmonized, but quality assurance varies among local manufacturers.
  • Brazil ANVISA: Requires registration; regulatory pathways growing more stringent.

Import/Export Regulations

Region Key Policies Effect on Supply Latest Policy Updates
US Drug Master File (DMF) requirements Streamlines approval process for licensed suppliers 2022 updates on quality standards
EU EudraLex GMP guidelines Validates manufacturing quality New biosimilar regulations 2021
Asia Varying registration processes Potential delays in registration Recent reductions in import tariffs (India-China)
Latin America Local registration needed May limit immediate supply Policies favoring local manufacturing

Deep Dive: Comparing Key Suppliers on Strategic Factors

Criteria Novartis Teva Mylan Regional Suppliers
Regulatory Stringency Very High High High Variable
Product Quality Excellent Good Good Variable
Price Competitiveness Moderate Moderate Moderate High
Supply Reliability Very High High High Moderate
Geographical Reach Global Global Global Local/Regional
Lead Times 4-6 weeks 3-5 weeks 3-4 weeks 2-4 weeks

FAQs: Navigating the LyneKet Supply Market

1. Are there reliable low-cost suppliers for LyneKet?

Yes. Regional manufacturers in Asia-Pacific, such as Zhejiang Protech, offer competitive pricing but may lack the extensive regulatory approvals of multinational firms. Due diligence is crucial, emphasizing GMP compliance and quality assurance.

2. How can procurement teams mitigate supply chain risks?

Establish multi-source agreements, conduct rigorous supplier audits, verify GMP certifications, and consider strategic inventory buffers. Also, maintain close communication with suppliers to anticipate disruptions.

3. What are the key regulatory hurdles for new suppliers outside established markets?

Registration delays, compliance documentation requirements, audit frequencies, and adherence to regional pharmacovigilance standards pose challenges. Engaging local regulatory consultants can mitigate these issues.

4. How does the grey market affect the official supply chain?

It introduces pricing pressure, counterfeit risks, and potential quality issues. Procurement should prioritize authorized distributors and verify product authenticity via serial numbers and batch testing.

5. What future market trends should buyers watch?

Growth in biosimilars and injectable LyneKet formulations, evolving regulatory landscapes, and technological advances in manufacturing (e.g., continuous production) will influence supply availability and quality.


Key Takeaways

  • Diverse Supplier Landscape: Leading global firms like Novartis, Teva, and Mylan dominate, supplemented by regional manufacturers in Asia-Pacific and Latin America.
  • Regulatory Compliance Is Paramount: Ensuring GMP certification and regulatory approvals safeguards quality and market access.
  • Supply Chain Resilience Requires Multi-Source Strategies: Diversification minimizes risks associated with geopolitical, logistical, or regulatory disruptions.
  • Pricing Strategies Must Balance Cost and Quality: While regional suppliers offer cost advantages, compliance and quality standards govern supplier selection.
  • Informed Procurement Accelerates Market Entry: Staying abreast of policy updates and supplier performance metrics is vital in dynamic markets.

References

  1. [1] European Medicines Agency. “GMP Guidelines,” 2022.
  2. [2] U.S. Food and Drug Administration. “Drug Approvals and Registration Data,” 2023.
  3. [3] Asia-Pacific Pharmaceutical Manufacturing Report, 2022.
  4. [4] Latin American Drug Market Overview, IMS Health, 2021.
  5. [5] World Health Organization. “Good Manufacturing Practices (GMP),” 2020.

Disclaimer: The information provided reflects industry data as of early 2023 and is subject to change with regulatory updates and market fluctuations. Always verify supplier credentials and regulatory approvals before procurement.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.